Press release
Anavex Life Sciences Announces Notice of Allowance for U.S. Patent Application ANAVEX®2-73 (blarcamesine) for the Treatment of Cardiac Dysfunctions
Issuance of Its Newest U.S. Patent Will Strengthen Anavex’s Compounds Intellectual Property Portfolio NEW YORK, June 03, 2021 (GLOBE NEWSWIRE) -- Anavex Life
About this update from Anavex Life Sciences Corp.
[{"type":"text","content":"Issuance of Its Newest U.S. Patent Will Strengthen Anavex’s Compounds Intellectual Property Portfolio\nNEW YORK, June 03, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) disorders, today announced it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent application number 16/166,732 expanding coverage of treatment methods for ANAVEX®2-73 (blarcamesine), to the treatment of a range of cardiac dysfunctions including cardiac arrhythmia, ventricular arrhythmia and atrial fibrillation among other indications. Data suggests that activation of the sigma-1 receptor is pivotal to restoring neural cell homeostasis and promoting neuroplasticity.1 Anavex’s newest patent is expected to remain in force at least until 2038, not including any patent term extensions. The new patent will expand the use of ANAVEX®2-73 (blarcamesine) from neurodegenerative and neurodevelopmental disorders to a range of cardiac dysfunctions. “This new use of ANAVEX®2-73 (blarcamesine) will be exceptionally important for Alzheimer’s disease patients because the advanced age of these patients make them also more susceptible to heart disease,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, adding: “We are extremely pleased with the continued development of the patent portfolio for ANAVEX®2-73 (blarcamesine). When it issues, this new patent will fortify our robust patent portfolio relating to ANAVEX®2-73 (blarcamesine), and further demonstrate our strong overall commitment to protecting the innovation and commercial opportunity of our product portfolio”. About Cardiac Dysfunction Heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups in the United States. About 655,000 Americans die from heart disease each year — that is 1 in every 4 deaths.2 Heart disease costs the U.S. about $219 billion each year — this includes the cost of health care services, medicines, and lost productivity due to death.3 Cardiac dysfunctions may be caused by a...